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Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may
yield endocrine resistance in metastatic breast cancer (MBC) patients. These
putative endocrine resistance markers are likely to emerge during treatment,
and therefore, its detection in liquid biopsies, such as circulating tumor cells
(CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed
to determine whether ESR1 mutations and splice variants occur more fre-
quently in CTCs of MBC patients progressing on endocrine treatment. In
addition, the presence of ESR1 mutations was evaluated in matched cfDNA
and compared to CTCs. CellSearch-enriched CTC fractions (≥5/7.5 mL) of
two MBC cohorts were evaluated, namely (a) patients starting first-line endo-
crine therapy (n = 43, baseline cohort) and (b) patients progressing on any
line of endocrine therapy (n = 40, progressing cohort). ESR1 hotspot muta-
tions (D538G and Y537S/N/C) were evaluated in CTC-enriched DNA using
digital PCR and compared with matched cfDNA (n = 18 baseline cohort;
n = 26 progressing cohort). Expression of ESR1 full-length and 4 of its splice
variants (Δ5, Δ7, 36 kDa, and 46 kDa) was evaluated in CTC-enriched
mRNA. It was observed that in the CTCs, the ESR1 mutations were not
enriched in the progressing cohort (8%), when compared with the baseline
cohort (5%) (P = 0.66). In the cfDNA, however, ESR1 mutations were more
prevalent in the progressing cohort (42%) than in the baseline cohort (11%)
(P = 0.04). Three of the same mutations were observed in both CTCs and
cfDNA, 1 mutation in CTCs only, and 11 in cfDNA only. Only the Δ5 ESR1
splice variant was CTC-specific expressed, but was not enriched in the pro-
gressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in
CTC-enriched fractions was lower than for cfDNA. ESR1 mutations
detected in cfDNA, rarely present at the start of first-line endocrine therapy,
were enriched at progression, strongly suggesting a role in conferring endo-
crine resistance in MBC.
Abbreviations
AI, aromatase inhibitor; cfDNA, cell-free DNA; CTC, circulating tumor cell; dPCR, digital PCR; HBD, healthy blood donor; MBC, metastatic
breast cancer; PD, progressive disease; SD, standard deviation; VAF, variant allele frequency.
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1. Introduction
Endocrine therapy is the mainstay of treatment for
estrogen receptor (ER)-positive metastatic breast can-
cer (MBC) patients. However, 40% of these patients
obtain no clinical benefit from first-line endocrine ther-
apy, and virtually all of the patients in whom the tumor
initially responds will eventually develop resistance
(Pritchard, 2013). Several mechanisms have been linked
to endocrine resistance (De Marchi et al., 2016), but
none of these have been implemented in daily clinical
practice because their clinical value could not be con-
firmed, or was not strong enough. One recently
revealed mechanism for acquired resistance is the emer-
gence of mutations in the gene coding for ER, ESR1,
yielding a constitutively activated ER. Functional stud-
ies have suggested that tumor cells with these mutations
are less responsive to estrogen deprivation as induced
by aromatase inhibitors (AIs) (Robinson et al., 2013;
Toy et al., 2013), but may still experience growth inhi-
bition by ER-blocking agents such as tamoxifen and
fulvestrant (Jeselsohn et al., 2014; Robinson et al.,
2013; Toy et al., 2013). This was recently supported in
a retrospective clinical analysis, in which a modest pro-
gression-free survival benefit was observed for MBC
patients with an ESR1 mutation who were treated with
fulvestrant, when compared to the AI exemestane
(Fribbens et al., 2016). These results have further
emphasized the potential for the determination of
ESR1 mutations to guide treatment decision making in
ER-positive MBC (Angus et al., 2017).
Another mechanism that potentially contributes to
acquired endocrine therapy resistance is the occurrence
of ESR1 mRNA splice variants. ESR1 splice variants
have been described as having various effects on the
transcriptional activity of the ER (Taylor et al., 2010),
and are heterogeneously expressed in primary breast
cancers (Poola and Speirs, 2001). The ERaΔ5 splice
variant is of particular interest, as preclinical experi-
ments have reported that this variant exerts constitu-
tional transcriptional activity (Bollig and Miksicek,
2000; Fuqua et al., 1991). However, to date, the puta-
tive role of ESR1 splice variants with regard to endo-
crine resistance in MBC has not been assessed.
ESR1 mutations and mRNA splice variants are likely
to emerge during treatment and can therefore only be
observed in tumor cells obtained during or after treat-
ment. Thus, these investigations require metastatic
tumor tissue obtained through biopsies, which can be
technically challenging, or even impossible.
Circulating tumor cells (CTCs) and circulating
tumor DNA (ctDNA) are alternative and minimally
invasive means of assessing the characteristics of meta-
static cancer cells. Theoretically, each acts as a differ-
ent substrate for DNA, with DNA from CTCs coming
from intact cancer cells, and ctDNA [which is part of
the total cell-free DNA (cfDNA)] is thought to origi-
nate mainly from apoptotic tumor cells (Haber and
Velculescu, 2014). The introduction of very sensitive
digital polymerase chain reaction (dPCR) assays has
opened new avenues to determine the presence of muta-
tions in ctDNA and in CTC-derived DNA of patients
with cancer. Although promising results have been
achieved with the detection of ESR1 mutations in
cfDNA using dPCR (Chu et al., 2015; Fribbens et al.,
2016; Guttery et al., 2015; Schiavon et al., 2015; Take-
shita et al., 2015, 2016; Wang et al., 2016), the impor-
tant advantage of using CTCs over cfDNA is that
multiple parameters in multiple dimensions (DNA,
RNA, and protein) can be measured in the same sample
and can be associated with, for example, endocrine resis-
tance. This implies that besides assessing mutations in
CTC-derived DNA, the characterization of RNA from
CTCs permits the assessment of splice variants.
The current study set out to evaluate ESR1 muta-
tions and splice variants in CellSearch-enriched CTCs
of MBC patients before the start of first-line endocrine
therapy, and during progression under any line of
endocrine therapy. The main objective was to deter-
mine whether these putative mechanisms for endocrine
resistance are enriched in patients progressing on
endocrine therapy. To this end, a cohort of MBC
patients before the beginning of first-line endocrine
therapy for MBC was defined, as well as a cohort of
MBC patients progressing under any line of endocrine
therapy. Additionally, in a subgroup of these patients,
the ESR1 mutation status in CTCs was compared with
patient-matched cfDNA.
2. Materials and methods
2.1. Patients and treatment
The patients evaluated in this study were selected from
two CTC studies comprising patients receiving endo-
crine therapy (study 06-248 (Mostert et al., 2015;
Onstenk et al., 2015b; Sieuwerts et al., 2011) and study
09-405 (Reijm et al., 2016)). Six centers in the Nether-
lands and Belgium participated in these studies from
February 2008 through March 2015. The patients were
included in these studies if they had MBC, and a new
line of endocrine therapy was begun. Blood was sam-
pled before the start of endocrine therapy and/or at
the time of progression to palliative endocrine
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treatment. At both of these time points, 10 mL of
blood was drawn for CTC enumeration, and another
10 mL of blood was drawn for CTC characterization.
In each participating center, the institutional board
approved the study protocols (Erasmus MC ID MEC-
06-248 and MEC-09-405). All patients provided writ-
ten informed consent.
Two cohorts of patients were defined for the current
study: a cohort starting first-line endocrine therapy for
MBC and a separate cohort progressing under any line
of palliative endocrine therapy. Further eligibility crite-
ria required that the patient had ≥5 CTCs/7.5 mL of
blood at the time of the blood draw, to allow for the
characterization of CTCs.
2.2. Enumeration and isolation of DNA and RNA
from CTCs and cfDNA and ESR1 mutation
determination
Details regarding the CTC enumeration and isolation of
DNA/RNA from CTCs have been reported previously
(Mostert et al., 2015; Onstenk et al., 2015b; Reijm
et al., 2016; Sieuwerts et al., 2011). Briefly, in each
patient, 10 mL of blood was drawn in CellSave tubes
(Janssen Diagnostics, Raritan, NJ, USA) for CTC enu-
meration, which was performed on 7.5 mL of blood
within 96 h of the blood draw using the CellSearch sys-
tem (Janssen Diagnostics). Another 10 mL of blood
was drawn into EDTA tubes for CTC characterization,
and CTCs were isolated from 7.5 mL of blood within
24 h using the CellSearch system with the CellSearch
profile kit (Janssen Diagnostics) (Fig. S1). Subsequently,
DNA and RNA were isolated from enriched CTCs
using the AllPrep DNA/RNA Micro Kit (Qiagen, Ger-
mantown, MD, USA) (Sieuwerts et al., 2011). For
cfDNA analyses, the remainder of the EDTA blood
(maximum of 2.5 mL) was centrifuged to isolate plasma
within 24 h after the blood draw. Cell-free DNA
(cfDNA) was isolated from a total of 200 lL of plasma
using the QIAamp circulating nucleic acid kit (Qiagen).
DNA from the CellSearch-enriched CTC fractions
and cfDNA from plasma were quantified using the
Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher
Scientific, Waltham, MA, USA). The DNA (0.1–
1 nglL1) was subjected to an ESR1 target-specific
amplification of 15 cycles with TaqMan PreAmp Master
Mix (Thermo Fisher Scientific), as recommended by the
manufacturer, using the ESR1 PreAmp primer combi-
nation (Table S1) at a final concentration of 400 nM
each. The resulting pre-amplified 136 base pair product
covering the positions of all four ESR1 hotspot muta-
tion sites (D538G and Y537S/C/N) was diluted 10-fold,
and quantified via regular quantitative PCR (qPCR) for
wild-type (WT) ESR1 using the same primers. The
resulting Cq value was used to control the number of
WT copies to be loaded onto the chips for dPCR analy-
ses. The variant allele frequencies (VAF) of the studied
mutations for ESR1 were evaluated with mutation-spe-
cific TaqMan assays (the primer and probe sequences
are given in Table S1, and the reproducibility of these
assessments in Fig. S2) via chip-based dPCR (QuantStu-
dio 3D; Thermo Fisher Scientific) according to the man-
ufacturer’s instructions. Positive and negative control
DNA was always included in each dPCR run, and all of
the analyzed DNA samples (CTC and cfDNA) were
evaluated in duplicate.
Digital PCR was performed for four ESR1 hotspot
mutation sites (D538G and Y537S/C/N). Ten healthy
blood donors were used to specify the cutoffs for the
presence of ESR1 mutations in CellSearch-enriched
samples. Seven of them had sufficient plasma avail-
able, and these samples were used to specify the cut-
offs for the presence of ESR1 mutations in cfDNA.
The cutoff for the positivity for each individual assay
was set at the highest VAF in the healthy blood
donors plus 2.58 standard deviations (SD) (99% confi-
dence interval) (Figs S3 and S4). The cutoffs were as
follows: D538G = 0.6% (CTCs) and 1.0% (cfDNA),
Y537S = 0.3% (for both CTCs and cfDNA),
Y537N = 0.3% (CTCs) and 1.65% (cfDNA),
Y537C = 0.5% (CTCs) and 0.65% (cfDNA). Both of
the duplicate ESR1 mutation measurements had to be
above the cutoffs for a sample to be considered posi-
tive for a specific ESR1 mutation.
2.3. Short tandem repeat analysis on patient-
matched CTC-DNA and cfDNA
In a subset of samples with ≥ 10 CTCs and a high
enough DNA content (≥ 30 ng) for which not all Cell-
Search-enriched DNA was used for ESR1 mutation
analysis, a short tandem repeat (STR) analysis was
performed to confirm that the CellSearch-enriched
DNA and cfDNA were indeed from the same donor.
The PowerPlex 16 System (Promega, Madison, WI,
USA), in combination with an ABI PRISM 3130xl
Genetic Analyzer (Thermo Fisher Scientific) and GENE-
MARKER v1.91 software (Softgenetics LLC, State Col-
lege, PA, USA), was used to genotype the DNA, as
recommended by the manufacturer’s instructions.
2.4. ESR1 splice variants and expression in RNA
from enriched CTCs
The measured ‘splice variant gene panel’ consisted of
full-length (FL) ESR1 and ESR1 splice variants Δ5,
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Δ7, 36 kDa, and 46 kDa. In addition, reference genes
and epithelial genes were evaluated. Two microlitre of
complementary DNA was pre-amplified in 15 cycles
with TaqMan assays and TaqMan PreAmp Master
Mix (Thermo Fisher Scientific), as recommended by
the manufacturer, using the gene panel combination
given in Table S1. After pre-amplification, each gene
was individually measured via qPCR with the same
TaqMan assay used in the pre-amplification. Positive
and negative controls were included in each individual
experiment to monitor the reproducibility of the mea-
surements (for reproducibility, see also Fig. S5).
The splice variants were assessed in CellSearch-
enriched fractions of 10 healthy blood donors to evalu-
ate the possible leukocyte expression of FL ESR1 and
splice variants. The splice variant gene panel was
always evaluated in duplicate, and the averages of the
duplicate measurements were used for further calcula-
tion. Only those samples with sufficient mRNA signal
(reference genes average ΔCq<26.5) and epithelial sig-
nal (KRT19/EPCAM average ΔCq<26.5), as described
previously (Onstenk et al., 2015a; Sieuwerts et al.,
2009, 2011), were used for further evaluation of splice
variants. The ΔCq values for the splice variants were
calculated relative to the FL ESR1. In those cases
where no expression could be measured for both the
splice variant and the FL ESR1, the sample was
excluded from the analysis.
2.5. Statistical considerations
The primary objective of this research was to investi-
gate whether ESR1 mutations were more frequently
observed in CTCs of MBC patients progressing on
endocrine therapy, than in those patients starting first-
line endocrine therapy. Based on data from the litera-
ture (Robinson et al., 2013; Toy et al., 2013), it was
hypothesized that ESR1 mutations in CTCs would be
detectable in 30% of MBC patients experiencing pro-
gressive disease (PD) during palliative endocrine ther-
apy and that ESR1 mutations in CTCs would be
present in 5% of those patients beginning palliative
first-line endocrine therapy. In order to detect this dif-
ference (a = 0.05 and b = 0.2), 44 MBC patients pro-
gressing on palliative endocrine therapy and 44 MBC
control patients initiating first-line endocrine therapy
were needed.
Secondary objectives included (a) an assessment of
ESR1 mutations in cfDNA samples, and a comparison
between the detection of ESR1 mutations in cfDNA
versus CTC; (b) an exploration of whether ESR1
mutations measured in cfDNA are enriched under
endocrine therapy; (c) an exploration of whether ESR1
splice variants are more prevalent in those patients
experiencing PD than in patients beginning first-line
endocrine therapy for MBC; and (d) an exploration of
whether certain clinical factors are associated with the
presence of ESR1 mutations and/or splice variants.
Differences in the prevalence of ESR1 mutation and
splice variants between the baseline cohort and the
progressing cohort were calculated using Fisher’s exact
test (two-sided), while those patients with matched
samples in the baseline and the progressing cohort
were excluded from this analysis. Correlations were
tested using Kendall’s tau correlation coefficient, and
the differences in splice variant ΔCq values between
groups were tested using the Kruskal–Wallis test. All
of the analyses were performed using Stata/SE version
12 (StataCorp LP, College Station, TX, USA), and all
of the data obtained from this study are available in
Doc. S1.
3. Results
3.1. Patient characteristics
For the baseline cohort, a total of 43 patient samples
were included, while the progressing cohort contained
a total of 40 patient samples (Table 1). Most of the
patients in the baseline cohort were not treated with
any adjuvant chemotherapy (79%); however, 17
patients (40%) had been treated with adjuvant endo-
crine therapy. Samples in the progressing cohort origi-
nated mainly from patients progressing on first-line
(55%) or second-line (30%) palliative endocrine ther-
apy. Prior to the PD sample, 37 patients (93%) had
received at least one line of AI treatment. Most
patients (81%) in the baseline cohort experienced PD
on endocrine therapy during the time of follow-up.
For six of these patients, matched samples from the
baseline cohort and progressing cohort were available;
however, for the other 29 patients, no PD sample was
available, mainly because it was not collected. The
median CTC count was higher in the baseline cohort
(81 CTCs/7.5 mL) than in the progressing cohort (21
CTCs/7.5 mL).
3.2. ESR1 mutations in CTCs and matched cfDNA
In the six matched samples from the baseline and pro-
gressing cohorts, no ESR1 mutations were detected.
ESR1 mutations were observed in the CTCs of two
(5%) baseline cohort samples (29 Y537N) and three
(8%) progressing cohort samples (29 D538G, 19
Y537S) (P = 0.66) (Table 2). One of the patients in the
baseline cohort with an ESR1 mutation had received
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prior adjuvant treatment with tamoxifen, while the
other patient had not received any prior adjuvant ther-
apy. Two of the ESR1 mutations in CTCs from
patients in the progressing cohort, occurring after pal-
liative first-line therapy, were observed in one patient
who had been treated with an AI and in one patient
who had been treated with tamoxifen. The third ESR1
mutation was observed in a patient progressing on ful-
vestrant as second-line palliative endocrine therapy,
who had received an AI as her first-line treatment.
Matched cfDNA and CTCs from the same time
point were available from a subset of the patients in
the baseline cohort (n = 18) and the progressing cohort
(n = 26) (Table S2). Two ESR1 mutations (19 D538G
and 19 Y537S) (11%) were observed in cfDNA of the
baseline cohort, and 12 ESR1 mutations were observed
in 11 patients (42%) in cfDNA of the progressing
cohort (89 D538G, 29 Y537S, 19 Y537N, 19
Y537C) (P = 0.04) (Table 2). In the four matched
cfDNA samples from the baseline and progressing
cohorts, no ESR1 mutations were detected. Neither of
the mutations found in cfDNA from the baseline
cohort were observed in the CTCs (Table 2). In one of
these patients, however, an Y537N mutation was
observed in CTCs, but not in cfDNA. Neither of the
patients with ESR1 mutations in cfDNA from the
baseline cohort had received any adjuvant therapy.
When the mutations in cfDNA from the progressing
cohort samples were compared with the mutation sta-
tus of the CTCs, three of three mutations observed in
CTCs were confirmed in cfDNA. With one exception,
variant allele frequencies (VAFs) of the mutations
were much higher in cfDNA than in CTCs (Table 2).
In addition, nine mutations in eight patients were
observed in the cfDNA, but not in the CTCs. The
mutations found in cfDNA of the progressing cohort
occurred after first-line endocrine therapies (n = 6),
namely AIs (n = 5) and tamoxifen (n = 1), and after
second-line endocrine therapies (n = 5), namely fulves-
trant (n = 3) and tamoxifen (n = 2). All of these latter
patients had received an AI as first-line palliative
endocrine treatment.
From four patients with matched CTC-cfDNA sam-
ples and discordant CTC versus cfDNA ESR1 muta-
tion results, unamplified DNA was available to
perform STR analyses (Table 2). These analyses
showed that both of the DNA fractions originated
from the same patient, and thus excluded sample
swapping.
3.3. ESR1 splice variants in CTCs
In order to assess the presence of ESR1 splice variants
in CTCs, RNA was extracted from CellSearch-
enriched CTCs and analyzed for the expression of four
ESR1 splice variants relative to full-length ESR1. In
the baseline cohort, 10 (23%) of the 43 samples were
excluded from further analysis, because of insufficient
quality of mRNA (n = 4) or lack of an epithelial signal
(n = 6). In the progressing cohort, 17 (43%) of 40
Table 1. Baseline characteristics
Parameter Description
Baseline cohort
(n = 43)
PD cohort
(n = 40)
Age at sample draw Median age (range) 72 (37–83) 63 (35–88)
Adjuvant endocrine therapy (%) No 26 (60) 26 (65)
Yes, tamoxifen only 10 (23) 9 (23)
Yes, tamoxifen + AI 5 (12) 4 (10)
Yes, AI only 2 (5) 1 (2)
Adjuvant chemotherapy (%) No 34 (79) 28 (70)
Yes 9 (21) 12 (30)
Neoadjuvant therapies (%) No 43 (100) 40 (100)
Number of previous lines endocrine therapy lines for MBC (%) 0 43 (100)
1 22 (55)
2 12 (30)
≥3 6 (15)
Endocrine therapy after start (BL cohort) or before PD (PD cohort) (%) AI 30 (70) 25 (63)
Tamoxifen 13 (30) 7 (17)
Fulvestrant 8 (20)
Previous endocrine therapy lines for MBC (in case
of inclusion at PD on ≥second-line endocrine therapy) (%)
Yes, AI only 9 (23)
Yes, AI + tamoxifen 6 (15)
Yes, tamoxifen only 3 (7)
Progression on the current line (%) Yes 35 (81) 40 (100)
CTC count Median count (range) 81 (6–32492) 21 (5–2837)
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samples had to be excluded because of insufficient
quality of the mRNA (n = 2), lack of an epithelial sig-
nal (n = 6), or unavailable RNA (n = 9).
ESR1 splice variant ΔCq values relative to full-
length ESR1 were not correlated with CTC counts
(Fig. S6). ΔCq values of the Δ5 splice variant relative
to full-length ESR1 were significantly higher in
patients than in healthy blood donors (HBDs)
(Fig. 1A), but the Δ5 splice variant was not enriched
in the progressing cohort, when compared to the base-
line cohort (P = 0.39). When four matched samples,
taken from the baseline and progressing cohorts, were
analyzed from patients receiving first-line AI treat-
ment, the Δ5 splice variant was enriched at PD in two
of the patients (Fig. S7). The Δ7 and 36 kDa splice
variants were similarly expressed in patient samples
and HBDs (Fig. 1B,C). Nevertheless, for the four
matched samples from the baseline and progressing
cohorts, the Δ7 and 36-kDa splice variants were
enriched at PD in one and three patients, respectively
(Fig. S7). The 46-kDa splice variant was only observed
in patient samples and not in HBDs; however, this did
not reach statistical significance (Fig. 1D).
4. Discussion
The current study evaluated whether ESR1 mutations
and splice variants were enriched in CTCs from MBC
patients progressing under endocrine therapy. No
enrichment of any of these putative resistance
mechanisms in CTCs was observed after endocrine
therapy. However, cfDNA analyses did reveal an
enrichment of ESR1 mutations at the time of progres-
sion on endocrine therapy, when compared with before
the initiation of first-line endocrine treatment.
The observation that ESR1 mutations were more
frequently observed in cfDNA than in CTCs suggests
that cfDNA is a more sensitive substrate for the analy-
sis of ESR1 mutations than CTCs enriched by the
FDA-approved CellSearch system. This is also
reflected by the VAFs in the CTCs, which were gener-
ally low (range: up to 3.8%), as opposed to the VAFs
in the cfDNA, which were generally much higher
(range: up to 40%). One explanation for this difference
could be the presence of contaminating leukocytes fol-
lowing the CellSearch enrichment of CTCs, which we
had previously reported to be around 1000 leukocytes
(Sieuwerts et al., 2009), thereby decreasing the sensitiv-
ity for the detection of ESR1 mutations in CTCs.
However, our experiments suggesting those amounts
of leukocytes after CellSearch profile were conducted
in healthy donors in perfect circumstances with quick
processing. For the current study, materials from
patients were used which were sometimes shipped from
distant sites and processed within 24 h, which may
have resulted in a higher number of contaminating
leukocytes. Therefore, the numbers of leukocytes that
are present after CellSearch enrichment may be even
higher than 1000 leukocytes in some samples, which is
likely to decrease sensitivity for detecting ESR1
Table 2. Observed ESR1 mutations in CTC and cfDNA samples. All patients in whom a mutation was called in either CTCs or cfDNA, along
with clinical information. Shown percentages are variant allele frequencies. Called mutations are depicted in boldface.
CTC code Baseline CTCs Baseline cfDNA Adjuvant therapy PD CTCs PD cfDNA
Progression
on therapy
Prior therapies
for MBC
CTC798a D538G (0.14%) D538G (1.93%) None Not available Not available
CTC1581 Y537S (0.39%)b Y537S (0.47%) None Not available Not available
Y537N (0.42%) Y537N (0.05%)
CTC1571 Y537N (3.77%) Not available Tamoxifen Not available Not available
CTC1007a Not available Not available None Y537S (0.01%) Y537S (9.26%) Fulvestrant AI
CTC1364a Not available Not available None D538G (0.25%) D538G (40.05%) Tamoxifen AI
CTC1565a Not available Not available Tamoxifen + AI D538G (0.14%) D538G (5.14%) Fulvestrant AI
CTC1569 Not available Not available None Y537N (0.25%) Y537N (1.96%) AI
CTC1352 Not available Not available None D538G (0.47%) D538G (20.93%) AI Tamoxifen
CTC1567 Not available Not available None Y537S (1.98%) Y537S (1.21%) Tamoxifen
CTC1360 Not available Not available None D538G (0.52%) D538G (2.86%) AI
CTC1587 Not available Not available Tamoxifen D538G (0.84%) D538G (15.98%) Fulvestrant AI
CTC1406 Not available Not available Tamoxifen D538G (1.13%) D538G (10.18%) AI
CTC1393 Not available Not available None D538G (0.18%)
Y537C (0.23%)
D538G (27.1%)
Y537C (12.96%)
AI
CTC1410 Not available Not available Tamoxifen D538G (0.37%) D538G (23.84%) AI
a STR analysis confirmed that the CTC-DNA and cfDNA samples were from the same patient. For other samples, not enough DNA available
for STR analysis. bAverage VAF positive, but negative in duplicate analysis.
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mutations even more in those samples. Although
cfDNA analysis is also challenged by the contamina-
tion of wild-type DNA, our results suggest that this is
less of an issue in cfDNA than in CTCs.
The stringency of the cutoffs for ESR1 mutations,
now arbitrarily set at the highest VAF observed in
HBDs plus 2.58xSD (representing the 99% confidence
interval), could have played a role in the limited sensi-
tivity of ESR1 mutation detection in CTCs. When less
stringent cutoffs based on the highest VAF in HBDs
were explored (data not shown), slightly more ESR1
mutations were observed in CTCs; however, the
majority of these mutations were not observed in
cfDNA, suggesting that relaxing the cutoffs for ESR1
mutation positivity may lead to false-positive findings.
This stresses the need to include HBDs, and to be
stringent with setting the cutoff value for ESR1 muta-
tion positivity. Interestingly, the current study
observed one ESR1 mutation exclusively present in
CTCs, but not in cfDNA. This finding suggests that
some ESR1 mutations may be missed by cfDNA anal-
ysis only, albeit this observation may be merely anec-
dotal.
The current study is among the first to assess ESR1
mutations in a cohort of patients beginning first-line
endocrine treatment for MBC. While it has already
been recognized that primary breast cancers rarely har-
bor ESR1 mutations (Jeselsohn et al., 2014; Toy et al.,
2013), most studies thus far have evaluated patients
who had been pretreated with palliative endocrine
therapy, suggesting that these mutations become
enriched during treatment with AIs (Schiavon et al.,
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Fig. 1. Occurrence of splice variants in the baseline cohort, the progressing cohort, and healthy blood donors (HBDs). Boxes demonstrate
median and IQR; lines represent adjacent values (1.5*IQR). Observations were binned at ΔCq of 0.5.
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2015). Here, it has been confirmed that ESR1 muta-
tions are not frequently present in MBC patients
before first-line endocrine therapy, and are enriched in
MBC patients progressing under endocrine therapy.
Most of the patients in this study having an ESR1
mutation progressed on AI treatment or had previ-
ously been treated with an AI. In three of the patients,
ESR1 mutations were observed after progression on
fulvestrant, suggesting that although it has been
reported that fulvestrant is more effective than AIs in
ESR1-mutant patients (Fribbens et al., 2016; Spoerke
et al., 2016), mutant subclones can still be observed at
PD on fulvestrant therapy. Of further note is the fact
that in the current study the observed mutations in the
baseline cohort occurred in those patients who were
not pretreated with AIs, or who received no pretreat-
ment with endocrine therapy at all. In addition, an
ESR1 mutation was observed in CTCs and cfDNA of
one patient progressing on first-line palliative tamox-
ifen therapy, but who had not received any AI treat-
ment, also not in the adjuvant setting. These findings
are in line with the observations of multiple groups
(Guttery et al., 2015; Jeselsohn et al., 2014; Takeshita
et al., 2015), who reported ESR1 mutations in meta-
static biopsies or cfDNA of patients who had only
received tamoxifen, or no pretreatment at all. This
could also fit with the observations by Wang et al.
(2016), who reported that ESR1 mutations were some-
times present in primary breast cancers of patients at
extremely low VAFs.
In the current study, the ESR1 splice variant Δ5 was
expressed at higher levels in the CellSearch-enriched
samples from MBC patients than in HBD samples;
however, we found no enrichment of this splice variant
during endocrine therapy for MBC. The Δ7, 36-kDa,
and 46-kDa splice variants were not significantly more
highly expressed in patients versus HBDs. The fact
that full-length ESR1 and splice variants were also
measured in a subset of HBDs suggests that leuko-
cytes, which are known to express ESR1 (Scariano
et al., 2008), may also express these splice variants.
This clearly complicates the analysis of ESR1 splice
variants measured in CellSearch-enriched CTC frac-
tions, where one thousand-fold of leukocytes is still
present. In metastatic prostate cancer, the presence of
the androgen receptor (AR) splice variant V7 in CTCs
was previously demonstrated to be strongly associated
with resistance to endocrine agents (Antonarakis et al.,
2014), but not to chemotherapy (Antonarakis et al.,
2015; Onstenk et al., 2015a; Scher et al., 2016). It
should, however, be noted that splice variants of
ESR1 in breast cancer differ importantly from splice
variants of the AR, as ESR1 splice variants are also
expressed in healthy breast tissue (Poola and Speirs,
2001), and full-length AR and splice variants are typi-
cally absent in CellSearch-enriched fractions of HBDs
(Onstenk et al., 2015a). It should also be kept in mind
that, in the current study, only a limited number of
samples could be evaluated for the presence of splice
variants. However, given that the ESR1 splice variant
Δ5 has been linked to endocrine resistance (Bollig and
Miksicek, 2000; Fuqua et al., 1991), is CTC-specific
expressed, and that we found anecdotal evidence of
enrichment of this splice variant in paired samples, fur-
ther research of this splice variant in CTCs is war-
ranted.
5. Conclusion
ESR1 mutations and splice variants in CellSearch-
enriched CTCs were not enriched in MBC patients
progressing on palliative endocrine therapy, but ESR1
mutations were enriched in those patients when they
were assessed in cfDNA. Therefore, cfDNA appears to
be a more sensitive and robust source for detecting
ESR1 mutations than DNA from CellSearch-enriched
CTCs. However, the use of other CTC enrichment
methods might yield better results (Denis et al., 2016).
To improve the sensitivity and specificity of detecting
mutations and splice variants, and to really exploit the
potential power of CTCs, characterization of pure
CTCs with single cell isolation systems is probably
required (Swennenhuis and Terstappen, 2015). Until
that has been proven feasible and superior to analysis
of cfDNA, the detection of ESR1 mutations in cfDNA
rather than CTCs is recommended. The increased inci-
dence of ESR1 mutations in cfDNA at the time of
progression on endocrine therapy further adds to the
evidence that emergence of ESR1 mutations is
involved in resistance to endocrine therapy in MBC.
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